• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Accolade Welcomes Renalogic to Trusted Partner Ecosystem

    10/15/24 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary
    Get the next $ACCD alert in real time by email

    Partnership will drive cost savings for customers while providing high-touch services that improve health outcomes to members with chronic kidney disease (CKD). 

    SEATTLE, Oct. 15, 2024 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) today announced that Renalogic, the recognized industry leader that manages the human and financial costs of chronic kidney disease (CKD) for self-insured employers and their members, will join the company's Trusted Partner Ecosystem, to offer its proven CKD risk management and dialysis cost containment solutions.

    Accolade Logo (PRNewsfoto/Accolade)

    Employers' health costs are expected to rise, with the average cost for employer sponsored care reaching $16,000 per employee in 2025, according to a recent report from Aon. A small portion of any employee population is affected by late-stage chronic kidney disease (CKD), but that population drives disproportionately high costs for employers due to the significant expenses associated with dialysis, especially for those who begin dialysis unexpectedly in an acute setting. Medicare often assumes responsibility for in-center dialysis costs from commercial payers after 33 months, but Renalogic helps employers control costs during that initial period while also improving outcomes.

    Renalogic helps self-insured health plans combat high dialysis costs and improve health outcomes in several ways:

    • Through ImpactIQ, Renalogic leverages its proprietary data algorithms to stratify members who are both diagnosed and undiagnosed with CKD, which gives insight into future high-cost claims and a path to tailored interventions. Renalogic's data algorithms are actuarially proven to be more than two times better at identifying undiagnosed CKD than the traditional marketplace.
    • These identified members can benefit from ImpactAdvocate to forestall end-stage renal disease (ESRD) and properly manage dialysis starts when necessary. ImpactAdvocate consistently reduces emergent starts by 30-50%, a critical opportunity to improve survival rates and save as much as $50,000 per emergent start. Additionally, Renalogic clients see their health plan members elect home dialysis services at two times the national average, the result of the education and support of ImpactAdvocate services.
    • Through ImpactProtect, Renalogic advises plans regarding fair market rates for dialysis services, leveraging proprietary methodologies that can save employers 50-80% against contracted rates on dialysis claims costs, which often equates to net savings of $75,000 - $125,000 per member on dialysis per year. 

    "We are excited to welcome Renalogic to Accolade's Trusted Partner Ecosystem as our first partner solution dedicated to CKD," said Dr. Connie Hwang, Accolade's Chief Clinical Officer. "Late-stage CKD is a complex and challenging condition that significantly impacts our members' quality of life. By integrating Renalogic's specialized clinical and administrative services, we will empower our members to better manage this complicated disease and ensure they receive the tailored care and support they need through every stage of their journey."

    "We are thrilled to join forces with Accolade to bring our expertise and proven methodology to their valued customers," said Kevin Weinstein, Renalogic's CEO. "With the incidence of late-stage CKD accelerating and dialysis costs averaging $250,000 per member per year, we are excited to empower Accolade's customers to navigate and lower these overwhelming costs. Together, we are committed to delivering significant value and improving outcomes for those managing CKD."

    Accolade and Renalogic will provide integrations to joint customers to promote awareness of Renalogic's services at no incremental cost, which includes warm handoffs from Accolade Care Advocates to Renalogic's clinical team.

    Representatives from Accolade and Renalogic will participate in an upcoming webinar to discuss the new partnership.

    Accolade's Trusted Partner Ecosystem

    Launched in 2019, Accolade's Trusted Partner Ecosystem accelerates the performance of digital health solutions to improve outcomes across valued categories for employers. Accolade's ecosystem currently consists of 18 partners across 12 categories.

    Benefits teams can confidently select from thoroughly vetted solutions and enjoy streamlined contracting and implementation. Through qualified referrals, Accolade drives more engagement with partner solutions, leading to exponentially better health outcomes and better value. Learn more here.

    About Accolade

    Accolade (NASDAQ:ACCD) is a Personalized Healthcare company that provides millions of people and their families with exceptional healthcare experiences so they can live their healthiest lives. Accolade's employer, health plan, and consumer solutions combine virtual primary care and mental health, expert medical opinions, and best-in-class care navigation. These offerings are built on a platform engineered to care through predictive engagement of population health needs, proactive care that improves outcomes and cost savings, and by addressing barriers to access and continuity of care. Accolade consistently receives consumer satisfaction ratings of over 90%. For more information, visit accolade.com. Follow us on LinkedIn, X, Instagram, and  Facebook.

    About Renalogic

    Founded in 2002, Renalogic helps self-funded plans and their members manage the human and financial costs of chronic kidney disease (CKD) and dialysis treatment. Renalogic helps plans manage dialysis claims with cost-containment and care management solutions while working to prevent members from progressing to dialysis with our advocacy and clinical care programs. These solutions and programs have helped Renalogic clients save hundreds of millions of dollars and helped stop CKD from progressing for thousands of members. For more information, visit renalogic.com/. Follow us on LinkedIn and Facebook.

    Accolade welcomes Renalogic to Trusted Partner Ecosystem

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accolade-welcomes-renalogic-to-trusted-partner-ecosystem-302276201.html

    SOURCE Accolade, Inc.

    Get the next $ACCD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD

    DatePrice TargetRatingAnalyst
    6/28/2024$13.00 → $8.00Buy
    Needham
    2/26/2024$16.00Outperform
    Leerink Partners
    1/17/2024$16.00 → $14.00Neutral
    DA Davidson
    1/3/2024$13.00Equal Weight
    Barclays
    5/24/2023$16.50Neutral → Buy
    BofA Securities
    4/12/2023$18.00Overweight
    Stephens
    3/23/2023$16.00Neutral → Buy
    Guggenheim
    2/9/2023$14.00Buy → Hold
    Jefferies
    More analyst ratings

    $ACCD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Transcarent Completes Merger With Accolade

    Creating the Most Comprehensive Health and Care Platform for Employers and Health Plans Serving 20 Million Members & 1,700 Employer and Health Plan Clients Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407811112/en/ With the completion of the transaction, Transcarent will offer a health and car

    4/8/25 9:22:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Stockholders Approve Merger Between Accolade and Transcarent

    SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the "Special Meeting") held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission. The transaction remains on track to be completed in the second quarter of calendar year 2025 and is subject to customary closing conditions, including the receipt of certain state regulatory approvals. Upon completion of the transaction, Accolade will become a privately held company and shares of Accol

    3/27/25 4:05:00 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

    Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE, March 6, 2025 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) has partnered with Oshi Health, a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.

    3/6/25 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    SEC Filings

    View All

    SEC Form 15-12G filed by Accolade Inc.

    15-12G - Accolade, Inc. (0001481646) (Filer)

    4/18/25 9:10:20 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by Accolade Inc.

    SCHEDULE 13D/A - Accolade, Inc. (0001481646) (Subject)

    4/10/25 9:03:06 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 25-NSE filed by Accolade Inc.

    25-NSE - Accolade, Inc. (0001481646) (Subject)

    4/8/25 3:43:21 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Accolade with a new price target

    Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously

    6/28/24 7:50:50 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Leerink Partners initiated coverage on Accolade with a new price target

    Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00

    2/26/24 7:00:19 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    DA Davidson resumed coverage on Accolade with a new price target

    DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously

    1/17/24 7:07:47 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Singh Rajeev returned $10,429,525 worth of shares to the company (1,483,574 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:52:21 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 4 filed by Director Lepore Dawn G

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:37:34 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Director Kent Cindy returned $84,093 worth of shares to the company (11,962 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:36:43 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Financials

    Live finance-specific insights

    View All

    Transcarent To Acquire Accolade

    Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil

    1/8/25 8:30:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade to Announce Fiscal Third Quarter 2025 Financial Results

    SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li

    12/16/24 8:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Announces Results for Fiscal Second Quarter 2025

    SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s

    10/8/24 7:00:29 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Leadership Updates

    Live Leadership Updates

    View All

    Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

    SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies. The transaction remains on track to be completed in the second quarter of calendar year 2025, subject to Accolade stockholder approval and satisfaction of other customary closing conditions. Glen Tullman, Chief Executive Officer of Transcarent, said, "With this milestone behind us, we ar

    2/24/25 5:20:27 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience

    Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo

    9/18/23 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade appoints new chief information security officer

    With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en

    7/25/22 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/12/24 12:26:15 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form SC 13G filed by Accolade Inc.

    SC 13G - Accolade, Inc. (0001481646) (Subject)

    11/4/24 11:51:44 AM ET
    $ACCD
    Business Services
    Consumer Discretionary